LFB S.A. Announces Achievement of Patient Enrollment Target for PerSept 1 Program for the Evaluation of Recombinant Factor Seven Efficacy by Prospective Clinical Trials

PARIS, France, December 17, 2014 — LFB S.A. announced today the achievement of patient enrollment target for PERSEPT 1, a multinational Phase 3 clinical trial of LR769, a novel recombinant form of human Factor VIIa, in adolescent and adult congenital hemophilia A or B patients with inhibitors.

This Phase 3 trial study is being sponsored by LFB S.A.’s US subsidiary.

LFB S.A. Announces That First Patient Has Begun Treatment with New Coagulation Factor VIIa (Recombinant) in Global Phase 3 Clinical Trial in Hemophilia A and B with inhibitors

FRAMINGHAM, MA, May 14, 2014 - LFB S.A., through its U.S. subsidiary, announced today that the first patient has begun treatment with LR769 in a Phase 3 clinical trial of this novel recombinant form of human Factor VIIa in patients with congenital hemophilia A or B with inhibitors. 

LFB S.A. Initiates Global Phase 3 Clinical Trial of New Coagulation Factor VIIA (Recombinant) in Patients with Hemophilia A and B

FRAMINGHAM, MA, March 3, 2014 —LFB S.A., through its rEVO Biologics subsidiary, announced today initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in patients with congenital hemophilia A or B with inhibitors. 
 
LR769 was developed using rPRO™ technology and is being developed for treatment and prevention of bleeding episodes in hemophilia A and B patients with inhibitors to Factor VIII or IX.